Tumor microenvironment-rearranging Nanoassemblies overcome angiogenesis-immunotherapy resistance to potentiate osteosarcoma treatment
A tumor-targeted nano-platform that co-delivers low-dose regorafenib with enzymatically versatile cerium oxide nanoparticles is engineered that could not only overcome the key limitations of conventional anti-angiogenic therapy but also provide a versatile and potent approach to sensitize osteosarcoma and other immunol...